For the year ending 2025-12-31, ANAB made $234,603K in revenue. -$13,561K in net income. Net profit margin of -5.78%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 234,603 | 91,280 | ||
| Research and development | 135,970 | 163,840 | ||
| General and administrative | 50,737 | 42,389 | ||
| Acquired in-process research and development | 0 | - | ||
| Total operating expenses | 186,707 | 206,229 | ||
| Income (loss) from operations | 47,896 | -114,949 | ||
| Interest income | 13,499 | 19,794 | ||
| Non-cash interest expense for the sale of future royalties | 79,893 | 50,087 | ||
| Other income (expense), net | 5,430 | 14 | ||
| Total other (expense) income, net | -60,964 | -30,279 | ||
| Loss before income taxes | -13,068 | -145,228 | ||
| (provision) benefit for income taxes | 164 | 3 | ||
| Net loss | -13,232 | -145,231 | ||
| Unrealized (loss) gain on available for sale securities | -329 | 1,102 | ||
| Comprehensive loss | -13,561 | -144,129 | ||
| Basic EPS | -0.46 | -5.12 | ||
| Diluted EPS | -0.46 | -5.12 | ||
| Basic Average Shares | 28,758,000 | 28,382,000 | ||
| Diluted Average Shares | 28,758,000 | 28,382,000 | ||
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)